On March 19, 2026 Kaida BioPharma, a biotechnology company developing targeted therapies for women with hard-to-treat gynecologic cancers, reported its executive leadership team and board. Each member brings decades of experience in biotechnology, clinical development, regulatory strategy, manufacturing, finance, and commercialization to help advance Kaida’s lead product candidate, KAD-101, toward first-in-human clinical evaluation. The company is developing KAD-101 for recurrent ovarian cancer, where treatment options narrow quickly and durable control remains limited.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kaida BioPharma is building KAD-101, a next-generation prolactin receptor antagonist for the ovarian cancer gap, the space where patients are too often left cycling through treatment with too few durable options.

In addition to her role as Chairperson of the Board, Kaida founder Dr. Stella Vnook has been named Acting Chief Executive Officer. Dr. Vnook is an accomplished biotechnology founder, executive, and advisor with extensive experience guiding early-stage therapeutics from scientific foundation through capital formation. At Kaida, she leads corporate strategy, development planning, and investor engagement.

"The science brought me here, and the women out there still fighting are why I stay. At Kaida, we are building for the ovarian cancer gap, for patients whose options narrow too fast and whose disease still outpaces available therapies," said Dr. Vnook. "By targeting the survival signals that keep these tumors alive, we believe KAD-101 has the potential to help overcome treatment resistance and create a new path toward more durable control. More options mean more time, and more time means everything."

Craig Pierson, a founder alongside Dr. Vnook, has been appointed Director at Kaida BioPharma. Mr. Pierson is a life sciences investor and company builder with more than 25 years of experience in investment banking and private capital formation. He provides strategic oversight and financing expertise.

George E. Peoples, MD, FACS has been appointed fractional Chief Medical Officer. Dr. Peoples is a surgical oncologist with decades of experience in translational oncology and clinical development. He is also the founder of the Cancer Vaccine Development Program, Cancer Insight, and LumaBridge. At Kaida, he helps guide clinical strategy and IND planning.

John Langenheim, PhD has been appointed fractional Chief Scientific Officer. Dr. Langenheim is a molecular biologist with more than 20 years of experience in therapeutic protein design and preclinical development. His scientific leadership has been instrumental in advancing KAD-101 toward clinical evaluation.

Pamela Swiggard has been appointed Head of Regulatory Affairs. She is a pharmaceutical executive with prior experience at companies including Pfizer and Endo Pharmaceuticals. She brings deep expertise across the product lifecycle, from development through regulatory approval and commercialization. At Kaida, she leads regulatory strategy and FDA engagement in support of IND readiness for KAD-101.

Eric Hacherl, PhD has been appointed Head of Manufacturing. Dr. Hacherl is a senior pharmaceutical operations leader with more than 25 years of experience in biologics manufacturing, cGMP compliance, and process development. At Kaida, he is responsible for helping ensure clinical supply readiness for KAD-101.

Mark Booth has been appointed Chief Commercial Officer. Mr. Booth is a seasoned pharmaceutical and biotechnology executive with more than 25 years of experience building commercial strategies for oncology and rare disease products. His background includes leadership across launch planning, brand strategy, access, and market development for important oncology products, including EMEND, EMEND IV, Zolinza, vintafolide, KEYTRUDA, and the avutometinib plus defactinib combination for low grade serous ovarian cancer. At Kaida, he is responsible for commercial strategy for KAD-101, including positioning, market development, and long-term access planning.

(Press release, Kaida BioPharma, MAR 19, 2026, View Source [SID1234663777])

On March 19, 2026 Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, reported a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company’s asset, CT-202, a Nectin-4 x CD3 TCE.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202
Abstract Number: 5392
Date and Time: Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT
Session Category: Clinical Research
Session: PO.CL05.12 – Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates
Location: Poster Section 48

For more information and to view the Company’s abstract, visit the AACR (Free AACR Whitepaper) Annual Meeting website. The poster will be made available in the Publications section of the Company’s website at the beginning of the poster session.

About CT-202
CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate ("ADC"), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment.

(Press release, Context Therapeutics, MAR 19, 2026, View Source [SID1234663776])

On March 19, 2026 Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to first-in-class small molecule MYB mRNA degrader, REM-422, for the treatment of patients with recurrent, metastatic or unresectable adenoid cystic carcinoma (ACC) whose tumors express MYB transcripts containing a poison exon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Receiving Fast Track designation for REM-422 underscores the urgent need for new treatment options for patients with ACC," said Peter Smith, PhD, Co-Founder and Chief Executive Officer of Remix Therapeutics. "REM-422 represents a novel approach designed to target MYB, a key oncogenic driver in ACC that has historically been difficult to drug. This designation supports our ongoing efforts to expeditiously advance REM-422 through clinical development to bring this potential therapy to patients as quickly as possible."

REM-422 is a first-in-class, oral small molecule MYB mRNA degrader designed to reduce MYB expression by inducing incorporation of a poison exon in the MYB transcript, leading to degradation of the mRNA and suppression of MYB protein expression. MYB dysregulation is a hallmark driver of ACC and several hematologic malignancies. REM-422 is currently being investigated in the ongoing Phase 1/2 ARIA (A study of REM-422 In Adenoid cystic carcinoma) study, evaluating safety, pharmacokinetics and preliminary anti-tumor activity in patients with recurrent or metastatic, and unresectable ACC.

The FDA’s Fast Track program is designed to accelerate the development and review of drugs that treat serious conditions and address unmet medical needs. The designation for REM-422 was based on positive preliminary results from a Phase 1 clinical trial evaluating REM-422 in patients with recurrent or metastatic ACC. REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-mechanism and proof-of-concept in ACC along with a favorable safety profile. Anti-tumor activity was observed in patients with recurrent, metastatic or unresectable ACC whose tumors express MYB transcripts containing a poison exon.

About REM-422
REM-422 is a first-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1/2 clinical studies in both Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S. Food and Drug Administration granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.

About the ARIA (A study of REM-422 In Adenoid cystic carcinoma) Clinical Trial
This Phase 1/2, open-label, non-randomized, multicenter study (NCT06118086) is investigating REM-422 in patients with recurrent, metastatic or unresectable Adenoid Cystic Carcinoma (ACC). The study includes a Dose Escalation Phase and a Dose Expansion Phase. The purpose of the Dose Escalation Phase is to determine the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of REM-422 in patients with recurrent, metastatic, or unresectable ACC. The purpose of Dose Expansion is to further evaluate the safety and anti-tumor activity of the REM-422 RP2D in biomarker positive patients.

About Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a solid tumor that most commonly arises in the salivary glands characterized by frequent recurrent, perineural invasion and dysregulation of the MYB oncogene. Depending on the location of the tumor, symptoms may include numbness of the face, difficulties swallowing, changes in vision, or difficulty breathing, among others. Many therapeutic approaches, such as chemotherapy, kinase inhibitors, and immunotherapy have been studied in ACC with modest or disappointing results, and there remain no approved treatment options.

(Press release, Remix Therapeutics, MAR 19, 2026, View Source [SID1234663775])

On March 19, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low breast cancer models.

Poster Presentation Details:

Title: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models
Date & Time: April 19, 2026 | 2:00 PM – 5:00 PM PT
Abstract Number: 329
The poster will be made available on the Scientific Publications page of the Company’s website following the presentation.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

(Press release, Cardiff Oncology, MAR 19, 2026, View Source [SID1234663774])

On March 19, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported financial results for the fourth quarter and full year ended December 31, 2025 and reviewed recent business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It’s an exciting time for the company as we build on strong maturing data and clinical momentum," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. "Our compelling data from ACR-368 in EC was well received at the ESGO Congress, reinforced by powerful commentary from world-renowned key opinion leaders at our live webcast, after the late-breaking oral presentation by Dr. Konstantinopoulos from the Dana- Farber Cancer Institute. Serous EC represents a particularly significant unmet need with a mortality rate resulting in 40-50% of all EC deaths. Through our rapidly maturing data, we are strategically generating multiple opportunities towards potential registration for ACR-368, including our announcement today of a fourth arm to our study to investigate ACR-368 monotherapy in biomarker-unselected serous EC subjects. Elsewhere in our pipeline, ACR-2316 has already shown promising clinical activity in lung cancer, underscoring the potential of its differentiated mechanism of action. Finally, we continue to build our pipeline with our next development candidate, ACR-6840, and new programs, reflecting our sustained AP3-driven innovation and commitment to long-term value creation."

Recent Highlights

ACR-368: CHK1 / CHK2 Inhibitor

Clinical data from the ongoing, registrational-intent ACR-368 Phase 2b trial was presented in a late-breaking oral presentation at the European Society of Gynecological Oncology (ESGO) Annual Congress by Dr. Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., from the Dana-Farber Cancer Institute
Consistent with higher BM levels in serous versus non-serous EC, an interim analysis across both OncoSignature-positive (BM+) and BM- serous EC subjects showed a cORR of 52% (N = 23) versus 22% (N = 37) in non-serous EC subjects; all subjects in this analysis received up to two prior lines of therapy (LoT), including chemotherapy and anti-PD-1
Based on this, Arm 3 was initiated in late 2025 to generate prospective data of ACR-368 with ULDG sensitization in all-comer (no pre-treatment biopsy or biomarker stratification) serous EC subjects with ≤2 prior LoT and is actively enrolling and dosing patients in the US, with 4 major EU countries on track to be activated by end of Q1 further accelerating enrollment through the addition of more than 20 EU sites
Following Dr. Konstantinopoulos’ presentation, the company hosted a KOL panel at ESGO, during which KOL experts expressed strong enthusiasm for ACR-368 and discussed the promising clinical data, emphasizing the high unmet need and potential impact for patients suffering from serous EC.
Building on promising clinical data and observed biomarker upregulation in serous EC, the company announced today that it plans to initiate a fourth cohort (Arm 4) in the ongoing ACR-368 Phase 2b study in the first half of 2026. This arm will enroll all-comer (BM-unselected) serous EC subjects, similar to Arm 3, but subjects will be treated with ACR-368 monotherapy and otherwise identical inclusion criteria to Arm 3.
Company also announced today that it has completed the exploratory Arm 2 of the study which treated BM- EC subjects with ≤3 prior LoT using ACR-368 with ULDG sensitization. Objectives of this arm were achieved, supporting that ULDG may contribute to ACR-368 efficacy in BM- subjects with a favorable tolerability profile.
ACR-2316: WEE1 / PKMYT1 Inhibitor

Initial data from the Phase 1 monotherapy dose-escalation trial showed a favorable tolerability profile and demonstrated clinical activity with tumor shrinkage, notably including partial responses and strong disease control in small cell lung cancer (SCLC) and squamous non-small cell lung cancer (NSCLC), tumor types predicted sensitive by AP3 not previously shown sensitive to WEE1 or PKMYT1 inhibitors in development

ACR-6840: Oral CDK11 Inhibitor

Nominated as internally-discovered development candidate from company’s AP3-driven cell cycle program

Strengthened Precision Medicine Therapeutics Capabilities

Launched wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory with full license to conduct patient sample testing and develop companion diagnostics

Anticipated Upcoming Milestones

ACR-368 Ongoing Registrational-Intent Phase 2b Study

Achieve CTA approval in EU for the ongoing (US) registrational intent serous EC all-comer Arm 3 (ACR-368 + ULDG) by Q1 2026
Initial clinical data from Arm 3 and additional update on Arm 1 of the ACR-368 Phase 2b trial in mid-2026
Initiate enrollment for the registrational intent serous EC all-comer Arm 4 (ACR-368) in the US in first half of 2026
Achieve readiness for Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy by mid-2026
Complete enrollment (up to N = 90 subjects) in the registrational intent serous EC all-comer Arm 3 (ACR-368 + ULDG) in Q4 2026

Broader Pipeline

Additional ACR-2316 Phase 1 clinical data for weekly and bi-weekly dosing regimens and transition into dose expansion in AP3-identified tumor types in 2026
Submit IND filing to the FDA for ACR-6840 in Q4 2026
Initiate additional internal programs utilizing the AP3 platform in 2026

Fourth Quarter and Full Year 2025 Financial Results

Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively. This compares to a net loss of $22.8 million and $80.6 million, respectively for the same periods in 2024.

Research and development expenses were $14.7 million for the quarter ended December 31, 2025, and $60.0 million for the full year 2025, compared to $18.6 million and $64.0 million, respectively, for the same periods in 2024. The difference was significantly driven by fewer milestones scheduled and incurred in the current period, as well as the prioritization of endometrial cancer in the ACR-368 clinical trial.

General and administrative expenses were $5.4 million for the quarter ended December 31, 2025, and $24.1 million for the full year 2025, compared to $6.3 million and $25.2 million, respectively, for the same periods in 2024. The difference was primarily due to a decrease in personnel costs, inclusive of non-cash stock compensation expense.

As of December 31, 2025, the company had cash, cash equivalents and investments of $118.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.

(Press release, Acrivon Therapeutics, MAR 19, 2026, View Source [SID1234663773])